Reconnecting

The current page stays visible while onset.to reconnects in the background.

Compass expects COMP360 psilocybin revenue in late Q2 or Q3 2027, subject to approval, scheduling and billing

Open original

Compass Pathways expects meaningful revenue from COMP360, its synthetic psilocybin treatment for treatment-resistant depression, in late Q2 or Q3 2027, following a slow initial ramp. The company completed its FDA application on November 9, 2026, but says review timing is uncertain. Reuters reported that the accelerated-review voucher program had been shelved, while HHS said the pilot continues; the report did not establish an effect on COMP360. Federal and state scheduling must precede much of the site certification and training Compass describes. Uptake also depends on patient affordability and payment for roughly six hours of monitoring, for which existing billing codes have no national payment rate. The projected revenue window requires an early FDA decision if scheduling takes the full time frames discussed.